Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma
Marie R. Webster(The Wistar Institute), Ashani T. Weeraratna(Johns Hopkins University), Ravi K. Amaravadi(University of Pennsylvania), Tara C. Mitchell(Hospital of the University of Pennsylvania), Lynn M. Schuchter(Eastern Cooperative Oncology Group), Andrew V. Kossenkov(The Wistar Institute), Gretchen M. Alicea(The Wistar Institute), Curtis H. Kugel(The Wistar Institute), Meenhard Herlyn(The Wistar Institute), Abibatou Ndoye(The Wistar Institute), Alexander A. Valiga(Thomas Jefferson University Hospital), Stephen M. Douglass(Johns Hopkins University), Giorgos C. Karakousis(Hospital of the University of Pennsylvania), Mitchell E. Fane(The Wistar Institute), Brett L. Ecker(Rutgers, The State University of New Jersey), Min Xiao(Tongji Hospital), Keerthana Gnanapradeepan(C4 Therapeutics (United States)), Amanpreet Kaur(The Wistar Institute), Cathy Zheng(University of Pennsylvania), Vito W. Rebecca(Johns Hopkins University), Maureen E. Murphy(The Wistar Institute), Qin Liu(University of Science and Technology of China), Hong Wu(Shanghai Tenth People's Hospital), Xiaowei Xu(University of Pennsylvania), Wei Xu(Peking University), Jessica Palmer(The Wistar Institute), Xiangfan Yin(The Wistar Institute), Jessicamarie Morris(The Wistar Institute), Subhasree Basu(The Wistar Institute), Gloria E. Marino(The Wistar Institute), Ying-Jie Wang(State Key Laboratory of Diagnosis and Treatment of Infectious Diseases), Filipe V. Almeida(The Wistar Institute)
Cited by 84
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Autophagy in major human diseases
|The EMBO Journal|2021|1.6k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Colorectal carcinoma antigens detected by hybridoma antibodies
|Somatic Cell and Molecular Genetics|1979|1.4k
A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas
|Cancer Research|2005|1.3k